Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- OncoTherapy Appoints Prof. Nakamura as Special Science Advisor
July 18, 2014
- Merck Serono Japan Hopes to Boost Erbitux Share by Narrowing Down CRC Patients: President
July 17, 2014
- Chugai, Zeltia Sign Commercialization Agreement for Plitidepsin in Europe
July 17, 2014
- AZ Begins Nexium Clinical Study for Pediatric Use in Japan
July 17, 2014
- Ono President Professes High Hopes for Newly Approved Anticancer Drug Opdivo
July 16, 2014
- Antiepileptic Treatment Aptiom Approved in Canada: Sumitomo Dainippon
July 16, 2014
- Astellas Files Irribow for Diarrhea-Predominant Irritable Bowel Syndrome in Females
July 16, 2014
- Ex-Astellas Chair Sounds Alarm over Oncology-Focused Businesses, Says Govt Finances Will Be Insufficient
July 15, 2014
- Kyowa Kirin’s UK Subsidiary Acquires Archimedes
July 15, 2014
- Otsuka Files NDA for Abilify Successor Drug Brexpiprazole in US
July 15, 2014
- “Favorable Transactions” for Nesp in Return for Support in Clinical Trial: Independent Panel
July 14, 2014
- Astellas, IBL to Study Manufacturing Method for Agent Utilizing Human Fibrinogen
July 14, 2014
- Takata Seiyaku Looks to Sales of 30 Billion Plus Yen by 2016
July 11, 2014
- Astellas Gearing Up to Expand Xtandi Indication Globally: Chief Medical Officer
July 11, 2014
- Astellas Selects Anticancer FLT3/AXL Inhibitor for Fast-Track Development
July 11, 2014
- Nippon Chemiphar Receives Approval for Actos Generic in Hong Kong: President
July 11, 2014
- Ono to Provide University of Tokyo with Access to Its Compound Library
July 11, 2014
- Bayer Yakuhin Adopts Unique Certificate Program to Train Cancer Sales Reps
July 10, 2014
- Novartis Lays Out New Global Guidelines for Investigator-Led Trials
July 10, 2014
- LSI Medience Develops Cardiotoxicity Assessment System Using Myocardial iPS Cells in NEDO-Driven Research Project
July 10, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…